These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35821751)

  • 21. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
    Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
    Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
    Pearsall SM; Humphrey S; Revill M; Morgan D; Frese KK; Galvin M; Kerr A; Carter M; Priest L; Blackhall F; Simpson KL; Dive C
    J Thorac Oncol; 2020 Dec; 15(12):1836-1843. PubMed ID: 32721553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
    Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
    Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.
    Metovic J; La Salvia A; Rapa I; Napoli F; Birocco N; Pia Bizzi M; Garcia-Carbonero R; Ciuffreda L; Scagliotti G; Papotti M; Volante M
    Endocr Pathol; 2022 Sep; 33(3):388-399. PubMed ID: 35608806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications.
    Akbulut D; Whiting K; Teo MY; Tallman JE; Ozcan GG; Basar M; Jia L; Rammal R; Chen JF; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Mehra R; Baine M; Bochner BH; Pietzak EJ; Bajorin DF; Rosenberg JE; Iyer G; Solit DB; Reuter VE; Rekhtman N; Ostrovnaya I; Al-Ahmadie H
    Mod Pathol; 2024 Oct; 37(10):100557. PubMed ID: 38964503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular features and evolutionary trajectory of ASCL1
    Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
    Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
    Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
    Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of Achaete-Scute Homologue-1 and Calcitonin Gene-Related Peptide during NNK-Induced Pulmonary Neuroendocrine Hyperplasia and Carcinogenesis in Hamsters.
    Naizhen X; Linnoila RI; Kimura S
    J Cancer; 2016; 7(14):2124-2131. PubMed ID: 27877229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
    Ito F; Sato T; Emoto K; Kaizuka N; Yagi K; Watanabe R; Hashiguchi MH; Ninomiya H; Ikematsu Y; Tanaka K; Domoto H; Shiomi T
    Mol Clin Oncol; 2021 Dec; 15(6):261. PubMed ID: 34790350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.
    He M; Liu S; Gallolu Kankanamalage S; Borromeo MD; Girard L; Gazdar AF; Minna JD; Johnson JE; Cobb MH
    Transl Oncol; 2018 Apr; 11(2):292-299. PubMed ID: 29413762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
    Eur Urol; 2024 Jun; 85(6):523-526. PubMed ID: 37380560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
    Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
    Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ASCL1 represses a SOX9
    Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
    Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56.
    Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y
    Am J Surg Pathol; 2020 Jun; 44(6):757-764. PubMed ID: 32118626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.
    Zhang W; Girard L; Zhang YA; Haruki T; Papari-Zareei M; Stastny V; Ghayee HK; Pacak K; Oliver TG; Minna JD; Gazdar AF
    Transl Lung Cancer Res; 2018 Feb; 7(1):32-49. PubMed ID: 29535911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.